Atara Biotherapeutics (ATRA) Operating Expenses (2013 - 2026)

Atara Biotherapeutics has reported Operating Expenses for 14 years, with the latest figure at $3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 93.45% year-over-year to $3.9 million; the trailing twelve-month figure through Mar 2026 stood at $29.4 million (down 86.18% YoY), and the FY2025 full-year result was $84.9 million, down 60.02% from the prior year.
• Operating Expenses for Q1 2026 stood at $3.9 million, down from $4.2 million in the prior quarter.
• The five-year high for Operating Expenses was $95.5 million in Q1 2022, with the low at $3.9 million in Q1 2026.
• Historically, Operating Expenses has averaged $54.7 million across 5 years, with a median of $61.9 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses gained 16.79% — and 2026, when it slumped 93.45%.
• Atara Biotherapeutics' Operating Expenses stood at $75.8 million in 2022, then declined by 15.24% to $64.2 million in 2023, then decreased by 29.99% to $45.0 million in 2024, then tumbled by 90.75% to $4.2 million in 2025, then fell by 6.57% to $3.9 million in 2026.
• The last three Operating Expenses figures came in at $3.9 million (Q1 2026), $4.2 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.